









Markets
/
Stocks
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

2.960USD

+0.160+5.71%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

778.60MMarket Cap

LossP/E TTM



Akebia Therapeutics Inc

2.960

+0.160+5.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

65 / 175

Overall Ranking

185 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

7.400

Target Price

+164.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Undervalued

The company’s latest PE is -16.88, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 112.41M shares, increasing 22.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 14.61M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.94, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 62.47M, representing a year-over-year increase of 43.13%, while its net profit experienced a year-over-year increase of 102.88%.

Score

Industry at a Glance

Previous score

8.94

Change



Financials

6.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -15.97, which is -81.80% below the recent high of -2.91 and 57.17% above the recent low of -6.84.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 9.20, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Akebia Therapeutics Inc is 7.00, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

7.400

Target Price

+164.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Akebia Therapeutics Inc

AKBA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.56, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 3.15 and the support level at 2.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.59

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Neutral

RSI(14)

43.913

Neutral

STOCH(KDJ)(9,3,3)

25.323

Buy

ATR(14)

0.134

High Vlolatility

CCI(14)

-72.064

Neutral

Williams %R

61.905

Sell

TRIX(12,20)

-0.586

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.892

Buy

MA10

2.947

Buy

MA20

3.025

Sell

MA50

3.373

Sell

MA100

3.266

Sell

MA200

2.630

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 42.78%, representing a quarter-over-quarter increase of 0.66%. The largest institutional shareholder is The Vanguard, holding a total of 14.61M shares, representing 5.51% of shares outstanding, with 13.84% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

13.97M

+0.96%

The Vanguard Group, Inc.

Star Investors

12.69M

+16.55%

State Street Global Advisors (US)

6.81M

+7.95%

Geode Capital Management, L.L.C.

5.03M

+4.91%

Alerce Investment Management, L.P.

5.75M

Satter Muneer A

5.75M

Morgan Stanley & Co. LLC

2.09M

+43.20%

Renaissance Technologies LLC

Star Investors

4.01M

+4.77%

Goldman Sachs & Company, Inc.

2.45M

+163.57%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.66, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.